Correlation Between Bristol Myers and Emergent Biosolutions

Can any of the company-specific risk be diversified away by investing in both Bristol Myers and Emergent Biosolutions at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bristol Myers and Emergent Biosolutions into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Bristol Myers Squibb and Emergent Biosolutions, you can compare the effects of market volatilities on Bristol Myers and Emergent Biosolutions and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bristol Myers with a short position of Emergent Biosolutions. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bristol Myers and Emergent Biosolutions.

Diversification Opportunities for Bristol Myers and Emergent Biosolutions

-0.46

Correlation Coefficient

Bristol Myers  Emergent Biosolutions

Very good diversification

The 3 months correlation between Bristol and Emergent is -0.46. Overlapping area represents the amount of risk that can be diversified away by holding Bristol Myers Squibb and Emergent Biosolutions in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Emergent Biosolutions and Bristol Myers is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bristol Myers Squibb are associated (or correlated) with Emergent Biosolutions. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Emergent Biosolutions has no effect on the direction of Bristol Myers i.e., Bristol Myers and Emergent Biosolutions go up and down completely randomly.

Pair Corralation between Bristol Myers and Emergent Biosolutions

Considering the 90-day investment horizon Bristol Myers Squibb is expected to generate 0.36 times more return on investment than Emergent Biosolutions. However, Bristol Myers Squibb is 2.81 times less risky than Emergent Biosolutions. It trades about 0.07 of its potential returns per unit of risk. Emergent Biosolutions is currently generating about -0.23 per unit of risk. If you would invest  5,545  in Bristol Myers Squibb on December 29, 2024 and sell it today you would earn a total of  345.00  from holding Bristol Myers Squibb or generate 6.22% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Bristol Myers Squibb  vs.  Emergent Biosolutions

Bristol Myers Squibb

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Bristol Myers Squibb are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal primary indicators, Bristol Myers may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Emergent Biosolutions

Risk-Adjusted Performance

Very Weak

Over the last 90 days Emergent Biosolutions has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental drivers remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Bristol Myers and Emergent Biosolutions

The main advantage of trading using opposite Bristol Myers and Emergent Biosolutions positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bristol Myers position performs unexpectedly, Emergent Biosolutions can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Emergent Biosolutions will offset losses from the drop in Emergent Biosolutions' long position.

The idea behind Bristol Myers Squibb and Emergent Biosolutions pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.